$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000114420417007071 Filed on February 09, 2017

Income Statement

Concept	2016 Q4	2016 Q1	2015 Q4
Revenue	$2.331M	$5.195M	$2.194M
YoY Change	6.24%	320.99%	60.97%
Cost Of Revenue	$1.727M	$1.036M	$836.0K
YoY Change	106.58%	14.6%	19.43%
Gross Profit	$604.0K	$4.159M	$1.358M
YoY Change	-55.52%	1156.5%	104.83%
Gross Profit Margin	25.91%	80.06%	61.9%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$1.526M		$3.174M
YoY Change	-51.92%		38.44%
% of Gross Profit	252.68%		233.75%
Depreciation & Amortization	$166.6K	$180.0K	$160.0K
YoY Change	4.13%	-357.14%	-23.81%
% of Gross Profit	27.58%	4.33%	11.78%
Operating Expenses	$2.326M	$3.588M	$4.071M
YoY Change	-42.86%	-38.01%	26.39%
Operating Profit	-$1.722M	$571.0K	-$2.713M
YoY Change	-36.53%	-110.46%	6.1%
Interest Expense	$55.56K		$68.12K
YoY Change	-18.43%		2.97%
% of Operating Profit
Other Income/Expense, Net	$1.519M	$7.408M	-$9.520M
YoY Change	-115.96%	-924.94%	-195.45%
Pretax Income	-$203.4K
YoY Change
Income Tax	$1.870M	-$520.0K	$0.00
% Of Pretax Income
Net Earnings	$1.667M	$8.499M	-$12.23M
YoY Change	-113.63%	-233.84%	-264.93%
Net Earnings / Revenue	71.51%	163.6%	-557.57%
Basic Earnings Per Share	$0.00	$0.03	-$0.05
Diluted Earnings Per Share	$0.00	$0.00	-$0.05
COMMON SHARES
Basic Shares Outstanding	904.8M shares	695.2M shares	684.8M shares
Diluted Shares Outstanding	910.5M shares		836.5M shares

Balance Sheet

Concept	2016 Q4	2016 Q1	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.28M	$11.51M	$8.100M
YoY Change	63.95%	54.29%	-2.06%
Cash & Equivalents	$13.28M	$11.51M	$8.103M
Short-Term Investments
Other Short-Term Assets	$760.0K	$380.0K	$390.0K
YoY Change	94.87%	-2.56%	18.18%
Inventory	$6.030M	$3.294M	$3.180M
Prepaid Expenses
Receivables	$540.0K	$1.530M	$750.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$20.62M	$16.71M	$12.42M
YoY Change	66.02%	35.55%	-5.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.720M	$8.111M	$7.660M
YoY Change	13.84%	26.69%	39.78%
Goodwill
YoY Change
Intangibles		$6.412M
YoY Change		0.47%
Long-Term Investments	$50.00K	$50.00K	$50.00K
YoY Change	0.0%	-75.0%	-16.67%
Other Assets	$390.0K	$437.7K	$645.6K
YoY Change	-39.59%	-45.7%	-3.35%
Total Long-Term Assets	$15.58M	$14.96M	$14.71M
YoY Change	5.91%	10.09%	17.59%
TOTAL ASSETS
Total Short-Term Assets	$20.62M	$16.71M	$12.42M
Total Long-Term Assets	$15.58M	$14.96M	$14.71M
Total Assets	$36.20M	$31.67M	$27.13M
YoY Change	33.43%	22.2%	5.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.360M	$1.804M	$3.040M
YoY Change	-55.26%	-46.67%	-5.3%
Accrued Expenses	$1.802M	$555.4K
YoY Change		-9.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$34.68K	$720.0K
YoY Change	-100.0%		7.46%
Long-Term Debt Due	$510.0K	$308.3K	$590.0K
YoY Change	-13.56%	16.25%	28.26%
Total Short-Term Liabilities	$4.680M	$4.640M	$5.360M
YoY Change	-12.69%	-8.46%	23.22%
LONG-TERM LIABILITIES
Long-Term Debt	$2.020M	$2.180M	$1.850M
YoY Change	9.19%	5.31%	-10.63%
Other Long-Term Liabilities	$29.18K	$47.42K	$21.99M
YoY Change	-99.87%	-92.46%	4634.86%
Total Long-Term Liabilities	$29.18K	$15.87M	$23.84M
YoY Change	-99.88%	-22.89%	-54.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.680M	$4.640M	$5.360M
Total Long-Term Liabilities	$29.18K	$15.87M	$23.84M
Total Liabilities	$10.15M	$20.51M	$29.20M
YoY Change	-65.24%	-20.04%	-48.08%
SHAREHOLDERS EQUITY
Retained Earnings		-$142.7M
YoY Change		0.48%
Common Stock		$109.8M
YoY Change		2.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$306.8K
YoY Change		0.0%
Treasury Stock Shares	100.0K shares	100.0K shares	100.0K shares
Shareholders Equity	$26.05M	-$33.12M	-$2.070M
YoY Change
Total Liabilities & Shareholders Equity	$36.20M	$31.67M	$27.13M
YoY Change	33.43%	22.2%	5.56%

Cashflow Statement

Concept	2016 Q4	2016 Q1	2015 Q4
OPERATING ACTIVITIES
Net Income	$1.667M	$8.499M	-$12.23M
YoY Change	-113.63%	-233.84%	-264.93%
Depreciation, Depletion And Amortization	$166.6K	$180.0K	$160.0K
YoY Change	4.13%	-357.14%	-23.81%
Cash From Operating Activities	-$730.0K	$600.0K	-$1.780M
YoY Change	-58.99%	-115.58%	-31.8%
INVESTING ACTIVITIES
Capital Expenditures	-$290.0K	-$570.0K	$40.00K
YoY Change	-825.0%	-5.0%	-110.26%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change
Cash From Investing Activities	-$290.0K	-$570.0K	$40.00K
YoY Change	-825.0%	-5.0%	-110.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.720M	3.370M	810.0K
YoY Change	112.35%	-7.67%	-77.75%
NET CHANGE
Cash From Operating Activities	-730.0K	600.0K	-1.780M
Cash From Investing Activities	-290.0K	-570.0K	40.00K
Cash From Financing Activities	1.720M	3.370M	810.0K
Net Change In Cash	700.0K	3.400M	-930.0K
YoY Change	-175.27%	-525.0%	-243.08%
FREE CASH FLOW
Cash From Operating Activities	-$730.0K	$600.0K	-$1.780M
Capital Expenditures	-$290.0K	-$570.0K	$40.00K
Free Cash Flow	-$440.0K	$1.170M	-$1.820M
YoY Change	-75.82%	-136.0%	-18.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1013333	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1013333	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-985619	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-816579	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2735085	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	149611	USD
	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	388915	USD
	eltp	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-148712	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1533080	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1802475	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	555352	USD
CY2016Q4	us-gaap	Loans Payable Current LoansPayableCurrent	439265	USD
CY2016Q1	us-gaap	Loans Payable Current LoansPayableCurrent	342944	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	29175	USD
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	47422	USD
CY2016Q4	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	900247	USD
CY2016Q1	eltp	Derivative Liability Warrants DerivativeLiabilityWarrants	10368567	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2518890	USD
CY2016Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3278887	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	9407	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9182021	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5131261	USD
	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	-23428573	USD
CY2016Q4	us-gaap	License And Services Revenue LicenseAndServicesRevenue	444884	USD
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	2330649	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1722423	USD
CY2015Q4	us-gaap	Interest Expense InterestExpense	68119	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	1666750	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-12232964	USD
CY2016Q4	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	0	USD
CY2015Q4	eltp	Change In Value Of Convertible Preferred Share Mezzanine Equity ChangeInValueOfConvertiblePreferredShareMezzanineEquity	-24785740	USD
CY2016Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-203364	USD
CY2016Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	3151	USD
CY2015Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
CY2016Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1666750	USD
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37018704	USD
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2016Q4	us-gaap	Interest Expense InterestExpense	55563	USD
CY2016Q4	us-gaap	Gross Profit GrossProfit	603898	USD
CY2015Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3174311	USD
CY2016Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1526183	USD
CY2015Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	654839	USD
CY2016Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	694321	USD
CY2015Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75025	USD
CY2016Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	84785	USD
CY2015Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	166825	USD
CY2016Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	21032	USD
CY2015Q4	us-gaap	Operating Expenses OperatingExpenses	4071000	USD
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	2326321	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2712799	USD
CY2016Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1519059	USD
CY2015Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9520165	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	258954	USD
	eltp	Stock Issued During Period Value Execution Of Warrants StockIssuedDuringPeriodValueExecutionOfWarrants	1847680	USD
	eltp	Park Capital Purchase Agreement ParkCapitalPurchaseAgreement	69425	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8800	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	87096	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5770163	USD
	eltp	Stock Issued During Period Value Payment Of Employee Salaries StockIssuedDuringPeriodValuePaymentOfEmployeeSalaries	13750	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	23571429	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	504932	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	492625	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-9468320	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	87999	USD
	eltp	Accrued Compensation Non Cash AccruedCompensationNonCash	1232950	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	272705	USD
	eltp	Increase Decrease In Deferred Revenue And Customer Deposits IncreaseDecreaseInDeferredRevenueAndCustomerDeposits	-759997	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3807871	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3371847	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-812054	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1378005	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	804762	USD
	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	1351847	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7292	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	26158	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1856480	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2455753	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	6391108	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5388952	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1771183	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	639100	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7464180	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8103280	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-434885	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-718309	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	135238	USD
	us-gaap	Interest Paid InterestPaid	142351	USD
	us-gaap	Interest Paid InterestPaid	127912	USD
	eltp	Commitment Shares Issued CommitmentSharesIssued	69425	USD
	eltp	Commitment Shares Issued CommitmentSharesIssued	37067	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5770163	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3289198	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	1278	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	1206	USD
	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	0	USD
	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	117095	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	290189	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	281237	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	17671	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	308834	USD
	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	384699	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	209366	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	210000	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	23571429	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2015Q4	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	-34237786	USD
CY2016Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	95279	USD
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2780918	USD
CY2015Q4	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	151761342	shares
	eltp	Effect Of Dilutive Instruments On Net Income EffectOfDilutiveInstrumentsOnNetIncome	30182606	USD
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	5742114	shares
CY2016Q4	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	5742114	shares
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	388959	USD
CY2016Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2015Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.0625
CY2016	eltp	Warrant Exercised Forfeitures And Expirations During Period WarrantExercisedForfeituresAndExpirationsDuringPeriod	48283968	shares
	eltp	Warrant Exercised Forfeitures And Expirations During Period WarrantExercisedForfeituresAndExpirationsDuringPeriod	32206847	shares
	eltp	Derivative Liability Warrants Change In Fair Value Of Warrant Liability DerivativeLiabilityWarrantsChangeInFairValueOfWarrantLiability	9468320	USD
CY2016Q4	eltp	Common Stock Traded Percent CommonStockTradedPercent	0.3	pure
CY2016Q4	eltp	Common Stock Weighted Average Price Percent CommonStockWeightedAveragePricePercent	0.97	pure
	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	833167	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7609667	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	870000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6472667	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.48
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.23
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1907000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	100000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5019335	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.29
CY2016Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2845247	USD
CY2016Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	222784	USD
CY2016Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	225698	USD
	us-gaap	Depreciation Depreciation	492625	USD
CY2016Q4	eltp	Bond Issue Costs BondIssueCosts	354453	USD
CY2016Q1	eltp	Bond Issue Costs BondIssueCosts	354453	USD
CY2016Q4	eltp	Accumulated Amortization Of Bond AccumulatedAmortizationOfBond	160686	USD
CY2016Q1	eltp	Accumulated Amortization Of Bond AccumulatedAmortizationOfBond	150052	USD
CY2016Q4	eltp	Unamortization Of Bond UnamortizationOfBond	193767	USD
CY2016Q1	eltp	Unamortization Of Bond UnamortizationOfBond	204401	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	64932	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	68986	USD
CY2016Q4	us-gaap	Interest Expense Debt InterestExpenseDebt	21603	USD
CY2015Q4	us-gaap	Interest Expense Debt InterestExpenseDebt	26081	USD
CY2016Q4	us-gaap	Deferred Revenue DeferredRevenue	3532223	USD
CY2016Q1	us-gaap	Deferred Revenue DeferredRevenue	4292220	USD
CY2015Q1	eltp	Warrants Outstanding WarrantsOutstanding	89870034	shares
CY2016Q1	eltp	Warrants Outstanding WarrantsOutstanding	41586066	shares
CY2016Q1	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.0625
CY2016Q4	eltp	Warrants Outstanding Weighted Average Exercise Price WarrantsOutstandingWeightedAverageExercisePrice	0.0625
CY2016Q4	eltp	Warrants Outstanding WarrantsOutstanding	9379219	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.09
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.21
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.19
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	904409	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	361298	USD
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	211665	USD
	eltp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue	317634	USD
CY2016	eltp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue	129913	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	333363	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS INC /NV/
	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Reclassifications</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Certain reclassifications have been made to the prior period financial statements to conform to the current period financial statement presentation. These reclassifications had no effect on net earnings or cash flows as previously reported.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	USD
CY2016Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	395.758	shares
CY2016Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	495.758	shares
CY2016Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2016Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2016Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	100	shares
CY2016Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	100	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15950718	USD
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14837122	USD
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	995000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	911245171	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	911145171	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	711544352	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	711444352	shares
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2016Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
	eltp	Intangible Assets Excluding Goodwill Acquired IntangibleAssetsExcludingGoodwillAcquired	7292	USD
CY2016Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	6411799	USD
CY2016Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	6381774	USD
CY2016Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1870114	USD
CY2015Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1870114	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>NOTE 10. COMMITMENTS AND CONTINGENCIES</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business.  The Company records a provision for a liability when it believes that is both probable that a liability has been incurred, and the amount can be reasonably estimated.  If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company’s condensed consolidated financial statements.  Contingencies are inherently unpredictable and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Legal Proceedings</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i> </i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i>Arbitration with Precision Dose, Inc.</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On May 9, 2014, Precision Dose Inc., the parent company of TAGI Pharmaceuticals, Inc., commenced an arbitration against the Company alleging that the Company failed to properly supply, price and satisfy gross profit minimums regarding Phentermine 37.5mg tablets, as required by the parties’ agreements. Elite denied Precision Dose’s allegations and has counterclaimed that Precision Dose is no longer entitled to exclusivity rights with respect to Phentermine 37.5mg tablets, and is responsible for certain costs, expenses, price increases and lost profits relating to Phentermine 37.5mg tablets and the parties’ agreements. The parties have reached agreement in settlement of these issues, with Precision Dose agreeing to pay certain amounts to the Company in exchange for Elite agreeing to restore exclusivity rights with respect to Phentermine 37.5mg tablets, subject to certain defined conditions. Both parties have been complying with the agreed settlement terms and the Company has notified the Arbitrator of this settlement, requesting the issuance of proceeding termination documents.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Due to the agreements reached and adhered to with regards to this issue, the Company has determined that no contingency loss needs to be recorded.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i> </i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Operating Leases 135 Ludlow Ave.</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company entered into an operating lease for a portion of a one-story warehouse, located at 135 Ludlow Avenue, Northvale, New Jersey (the “135 Ludlow Ave. lease”). The 135 Ludlow Ave. lease is for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15,000</font> square feet of floor space and began on July 1, 2010. During July 2014, the Company modified the 135 Ludlow Ave. lease in which the Company was permitted to occupy the entire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35,000</font> square feet of floor space in the building (“135 Ludlow Ave. modified lease”).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The 135 Ludlow Ave. modified lease, includes an initial term, which expires on December 31, 2016 with two tenant renewal options of five years each, at the sole discretion of the Company. On June 22, 2016, the Company exercised the first of these renewal options, with such option including a term that begins on January 1, 2017 and expires on December 31, 2021.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The 135 Ludlow Ave. property required significant leasehold improvements and qualifications, as a prerequisite, for its intended future use. Manufacturing, packaging, warehousing and regulatory activities are currently conducted at this location. Additional renovations and construction to further expand the Company’s manufacturing resources are in progress.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Rent expense is recorded on the straight-line basis. Rents paid in excess is recognized as deferred rent. Rent expense under the 135 Ludlow Ave. modified lease for the three-month ended December 31, 2016 and 2015 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">45,213</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">45,214</font>, respectively and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">135,639</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90,427</font> for the nine months ended December 31, 2016 and 2015 respectively. Rent expense is recorded in general and administrative expense in the unaudited condensed consolidated statements of operations. Deferred rent as of December 31, 2016 and March 31, 2016 was zero and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,528</font>, respectively and recorded as a component of other long-term liabilities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company has an obligation for the restoration of its leased facility and the removal or dismantlement of certain property and equipment as a result of its business operation in accordance with ASC 410, <i>Asset Retirement and Environmental Obligations Asset Retirement Obligations</i>. The Company records the fair value of the asset retirement obligation in the period in which it is incurred. The Company increases, annually, the liability related to this obligation. The liability is accreted to its present value each period and the capitalized cost is depreciated over the useful life of the related asset. Upon settlement of the liability, the Company records either a gain or loss. As of December 31, 2016 and March 31, 2016, the Company had a liability of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">29,177</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">27,895</font>, respectively and recorded as a component of other long-term liabilities.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Revenue Recognition Milestone Method Milestone RevenueRecognitionMilestoneMethodMilestone	The milestones, totaling $500k (with $405k already received), consist of amounts due upon the first shipment of each identified product, as follows: Phentermine 37.5mg tablets ($145k), Phentermine 15 &amp; 30mg capsules ($45k), Hydromorphone 8mg ($125k), Naltrexone 50mg ($95k) and the balance of $95k due in relation to the first shipment of generic products which still require marketing authorizations from the FDA, and to which there can be no assurances of such marketing authorizations being granted and accordingly there can be no assurances that the Company will earn and receive these milestone amounts.
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6726401	USD
	eltp	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.0	pure
CY2016	eltp	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.027	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.19	pure
	eltp	Milestone Issued For Epic Strategic Alliance Agreement Value MilestoneIssuedForEpicStrategicAllianceAgreementValue	0	USD
	eltp	Milestone Issued For Epic Strategic Alliance Agreement Value MilestoneIssuedForEpicStrategicAllianceAgreementValue	840000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.21	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.19	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.2	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.018	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.024	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.021	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.022	pure
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	6250	USD
CY2016Q1	us-gaap	Due To Employees Current DueToEmployeesCurrent	7500	USD
CY2016Q4	eltp	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.15
CY2016Q1	eltp	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.31
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	388959	USD
CY2016	eltp	Intangible Assets Excluding Goodwill Acquired IntangibleAssetsExcludingGoodwillAcquired	30025	USD
CY2016	eltp	Warrant Exercised Forfeitures And Expirations During Period Weighted Average Exercise Price WarrantExercisedForfeituresAndExpirationsDuringPeriodWeightedAverageExercisePrice
	eltp	Warrant Exercised Forfeitures And Expirations During Period Weighted Average Exercise Price WarrantExercisedForfeituresAndExpirationsDuringPeriodWeightedAverageExercisePrice
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7231333	USD
CY2015	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	5000000	USD

Files In Submission

Name	View Source	Status
0001144204-17-007071-index-headers.html	Edgar Link	pending
0001144204-17-007071-index.html	Edgar Link	pending
0001144204-17-007071.txt	Edgar Link	pending
0001144204-17-007071-xbrl.zip	Edgar Link	pending
eltp-20161231.xml	Edgar Link	completed
eltp-20161231.xsd	Edgar Link	pending
eltp-20161231_cal.xml	Edgar Link	unprocessable
eltp-20161231_def.xml	Edgar Link	unprocessable
eltp-20161231_lab.xml	Edgar Link	unprocessable
eltp-20161231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v458072_10q.htm	Edgar Link	pending
v458072_ex31-1.htm	Edgar Link	pending
v458072_ex31-2.htm	Edgar Link	pending
v458072_ex32-1.htm	Edgar Link	pending
v458072_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2016 Q4 Form 10-Q Financial Statement

#000114420417007071 Filed on February 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2016 Q4 Form 10-Q Financial Statement

#000114420417007071 Filed on February 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp